You are here: Industry Insights > CAR-T

News List

Novartis receives approval for Kymriah (tisagenlecleucel) by Health Sciences Authority as Singapore's first commercially approved CAR-T therapy prnasia
March 11, 2021
Novartis announced that the Health Sciences Authority (HSA) has approved Kymriah (tisagenlecleucel) as the first commercial chimeric antigen receptor T-cell (CAR-T) therapy in Singapore under the new cell, tissue and gene therapy products (CTGTP) ...
Thermo Fisher, JW Therapeutics Form CAR-T Partnership in China contractpharma
February 09, 2021
Thermo Fisher Scientific has signed an agreement with cell therapy company JW Therapeutics to ensure non-exclusive commercial access to Thermo Fisher's Gibco CTS Dynabeads CD3/CD28.
Tecartus wins NICE recommendation for mantle cell lymphoma pharmatimes
January 20, 2021
The UK’s National Centre for Health and Care Excellence (NICE) has recommended Kite’s CAR-T therapy Tecartus (autologous anti-CD19 transduced CD3+ cells) for the treatment of certain adult patients with relapsed or refractory mantle cell lymphoma ...
Bioheng Announced Oral Presentation of Its Preliminary Results of CRISPR-Engineered Allogeneic CAR-T for r/r B-ALL Treatment at 2020 ASH Meeting prnasia
November 13, 2020
Bioheng Biotech Co., Ltd, a clinical-stage biotechnology company focuses on developing novel cellular immunotherapy, announced that their preliminary data including the pre-clinical development, manufacturing, and investigator initiated trial (IIT) ...
Vor Biopharma signs exclusive license pact with NCI for clinical-stage CD33 CAR-T expresspharma
November 12, 2020
It is currently being evaluated in a multi-site Phase 1/2 clinical trial in children and young adults with relapsed or refractory acute myeloid leukemia (AML).
Novartis Expands with Kymriah Manufacturing Site in Asia americanpharmaceuticalreview
November 11, 2020
Novartis announced the receipt of marketing authorization from Japan’s Ministry of Health, Labor and Welfare (MHLW) for Foundation for Biomedical Research and Innovation at Kobe (FBRI) to manufacture and supply commercial Kymriah® (tisagenlecleucel) for..
PhoreMost, Oxford Biomedica Enter CAR-T Collaboration contractpharma
November 10, 2020
Aims to develop next-gen CAR-T cell therapies leveraging SITESEEKER and LentiVector platforms.
Novartis Expands Kymriah Manufacturing Footprint contractpharma
November 05, 2020
Novartis has received marketing authorization from Japan’s Ministry of Health, Labor and Welfare (MHLW) for Foundation for Biomedical Research and Innovation at Kobe (FBRI) to manufacture and supply commercial Kymriah (tisagenlecleucel) for patients ...
Leading Cell Therapy Company JW Therapeutics Lists on Main Board of HKEX prnasia
November 04, 2020
JW Therapeutics today celebrates the initial public offering (IPO) on the Main Board of the Stock Exchange of Hong Kong, S.A.R., China Limited.
CD19 CAR-T Therapy Manufactured Using Lonza’s Cocoon Platform contractpharma
September 18, 2020
MOH approves Cocoon Platform to manufacture a CD19 CAR-T cell immunotherapy for Phase II clinical trial for B-cell malignancies.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 13 14 Next page